Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Paul W. Armstrong, Burkert Pieske, Kevin J. Anstrom, Justin A. Ezekowitz, Adrian F. Hernandez, Javed Butler, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan A. Voors, Gang Jia, Steven E. McNulty, Mahesh J. Patel, Lothar Roessig, Joerg Koglin, Christopher M. O’Connor

New England Journal of Medicine, 2020

Canadian VIGOUR Centre, University of Alberta, Charité - Universitätsmedizin Berlin, Deutsches Herzzentrum der Charité, Duke University, Clinical Research Institute, Jackson Memorial Hospital, University of Mississippi Medical Center, National University of Singapore, National University Heart Centre Singapore, Wroclaw Medical University, University of Groningen, Merck & Co., Inc., Rahway, NJ, USA (United States), Bayer (Germany), Alaska Heart and Vascular Institute

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1257

Citations

View on Google Scholar

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Abstract

Journal Details

Join JournalsHub

Welcome Back